Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women

Abstract

We believe that centrally acting sympatholytic agent moxonidine is beneficial in the treatment of postmenopausal women with hypertension by reducing inflammatory cytokine TNFalpha without changing protective adiponectin level.